[HTML][HTML] Efficacy of a fourth dose of Covid-19 mRNA vaccine against Omicron
G Regev-Yochay, T Gonen, M Gilboa… - … England Journal of …, 2022 - Mass Medical Soc
G Regev-Yochay, T Gonen, M Gilboa, M Mandelboim, V Indenbaum, S Amit, L Meltzer…
New England Journal of Medicine, 2022•Mass Medical SocA Fourth Dose of mRNA Vaccine in Health Care Workers Health care workers in Israel were
given a fourth dose of BNT162b2 or mRNA-1273 vaccine during a period of omicron-variant
predominance. Levels of antibodies to SARS-CoV-2 had waned 5 months after a third dose,
and the fourth dose boosted antibodies to the maximum level observed after the third dose
but no higher. Vaccine efficacy was 31 to 43% against symptomatic disease.
given a fourth dose of BNT162b2 or mRNA-1273 vaccine during a period of omicron-variant
predominance. Levels of antibodies to SARS-CoV-2 had waned 5 months after a third dose,
and the fourth dose boosted antibodies to the maximum level observed after the third dose
but no higher. Vaccine efficacy was 31 to 43% against symptomatic disease.
A Fourth Dose of mRNA Vaccine in Health Care Workers
Health care workers in Israel were given a fourth dose of BNT162b2 or mRNA-1273 vaccine during a period of omicron-variant predominance. Levels of antibodies to SARS-CoV-2 had waned 5 months after a third dose, and the fourth dose boosted antibodies to the maximum level observed after the third dose but no higher. Vaccine efficacy was 31 to 43% against symptomatic disease.
The New England Journal Of Medicine